Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
Alexandre de NonnevilleAnthony GonçalvesChristophe ZemmourJean M ClasseMonique CohenEric LambaudieFabien ReyalChristophe SchererXavier MuracciolePierre E ColomboSylvia GiardRoman RouzierRichard VilletNicolas ChopinEmile DaraiJean R GarbayPierre GimberguesLaura SabianiCharles CoutantRenaud SabatierFrançois BertucciJean M BoherGilles HouvenaeghelPublished in: Breast cancer research and treatment (2017)
Adjuvant chemotherapy ± trastuzumab is associated with a significantly reduced risk of recurrence in subcentimeter node-negative HER2+ breast cancers. Most of the benefit may be driven by pT1b tumors.